Investor Presentaiton
Oncology
Opdivo
Opdualag
TIGIT Bispecific DGK Inhibitor
AR LDD
SC administration has clear benefits for patients, HCPs, and
healthcare systems
HCPs and Healthcare System
Logistical: Complex scheduling demands due
to higher patient volume1
Resource utilization: Overlapping duties for
staff, inefficient patient to nurse ratios 1,2
Patients
Time burden: Inconvenience 5, opportunity
cost/income loss6
Emotional burden: Loss of normality
long-term survivorship and 'chronic care'7
•
Reduces chair time (~5 min)³
•
Allows rapid drug delivery³
.
Reduces staff needed for administration³,4
•
Improves healthcare resource utilization³,4
•
•
Reduces time in clinic³
Improves scheduling and administration 8,9,10
Improves patient QOL 3,4,11
¹Lopez-Vivanco G. Clin Transl Oncol. 2017;19(12):1454-1461; 2Huang YL, et al. Journal of Oncology Practice. 2018; 14(2):e82-e91; 30'Shaughnessy J, et al. Eur J Cancer. 2021;152:223-232;
BA. Cancer. 2008;112(11 Suppl):2556-2568. Harvey MJ, et al. Plos One. 2022;17(1):e0261336. Jonaitis L, et al. BMC Proc. 2021;15(suppl 17):25. 10 Schreiber S, et al. Adv Ther. 2022;39:2342-2364.
11Dent S, et al. Curr Oncol. 2019;26(1):e70-e80.
ll Bristol Myers Squibb" "DuMond B, et al. J Oncol Pharm Prac. 2021;27(5):1214-1221. "De Cock E, et al. Cancer Med. 2016;5(3):389-397. 6Alzehr A, et al. Support Care Cancer. 2022;30(8):6385-6404. "Kim Y, Given
Not for Product Promotional Use
96View entire presentation